Metoclopramide-OROS Dispersible Tablets Optimized Formula Bioavailability Study

Samran Samran; Hari Ronaldo Tanjung

doi:10.3889/oamjms.2020.3353

Authors

Samran Samran Department of Pharmacy, STIKes Indah Medan, Medan, Indonesia
Hari Ronaldo Tanjung Department of Pharmacology, Faculty of Pharmacy, Universitas Sumatera Utara, Indonesia

DOI:

https://doi.org/10.3889/oamjms.2020.3353

Keywords:

Bioavailability, OROS dispersible tablet, Metoclopramide, Tapai extract

Abstract

BACKGROUND: Bioavailability and bioequivalence studies required by regulations to ensure therapeutic equivalence between a pharmaceutically equivalent test product and a reference product.

AIM: This study aimed to evaluate the bioavailability performance between the optimum formula of OROS dispersible tablet-metoclopramide dosage forms (FCL-6) and the Primperan® as the reference product.

METHODS: The FCL-6 formula was design by simplex lattice design model with a three components mixture of excipients: Solid tapai extract, corn starch, and Avicel. The optimum formula of OROS dispersible tablet (ODT)-metoclopramide consists of solid tapai extract (27.038 mg), corn starch (27.407 mg), and Avicel (53.555 mg), metoclopramide hydrochloric acid (HCl) (10.00 mg), LH-11 (22.50 mg), aspartame (5.00 mg), talcum BP (3.00 mg), and Mg stearate (1.50 mg). The in vivo test was done by cross-over design method using six rabbits. The level of metoclopramide concentration from in vivo test was measured by high-performance liquid chromatography instrument.

RESULTS: The study revealed that the tmax, Cmax, and area under curve (AUC) of ODT-metoclopramide FCL-6 were 60 min, 1.95 ± 0.13 μg/mL, and 1118.20 ± 150 μg/mL. min consecutively. The Cmax and the concentration of the drug absorbed in the blood (AUC) of ODT-metoclopramide were larger than Primperan® tablets. Statistical data of the optimized ODT-metoclopramide compared with Primperan® showed that the Cmax and AUC significance values were <0.05 (p < 0.05).

CONCLUSION: The optimized formula of ODT-metoclopramide revealed a better characteristic of Cmax and AUC concentration compared with Primperan®. The optimized ODT-metoclopramide with tapai extract was found to be promising to improved bioavailability of metoclopramide.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Plum Analytics Artifact Widget Block

References

Hirani JJ, Dhaval AR, Kantilal RV. Orally disintegrating tablets: A review. Trop J Pharm Res. 2009;8(2):161-72.

Laddha UD, Zilpelwar RV. Mouth dissolving tablet: A novel approach for better patient compliance. Int J PharmTech Res. 2015;8(6):56-64.

Ramu B, Ramakrishna N, Sathish M, Anoosha D. Formulation of telmisartan HCl fast disintegrating tablets by sublimation method. Int J PharmTech Res. 2015;8(3):330-9.

Shyamala B, Narmada GY. Rapid dissolving tablets: A novel dosage form. Indian Pharm. 2002;13(8):9-12.

Pawar SV, Junagade MS. Formulation and evaluation of mouth dissolving film of risperidone. Int J PharmTech Res. 2015;8(6):218-30.

Shah KR, Mehta TA. Design and development of fast disintegrating dosage form of taste masked lornoxicam. Int J PharmTech Res. 2015;8(4):581-94.

Samran, Karsono. Methochlopramide orally disintegrating tablet formulation using co-processed excipient of solid tapai extract and corn starch. Int J PharmTech Res. 2015;8(9):91-8.

Das IJ, Deepthi R, Rajashekar Y, Samal HB. Design and characterization of glimepiride fast dissolving tablets. Int J PharmTech Res. 2015;8(7):1-11.

Samran, Karsono, Simanjuntak MT, Silalahi J. Optimization of metoclopramide-orally disintegrating tablet using solid tape extract and corn starch. Indones J Pharm Sci. 2013;11(1):21.

CADTH; 2012. What are Bioavailability and Bioequivalence? Available from: https://www.cadth.ca/What_Are_Bioavailability_ and_Bioequivalence_e.pdf. [Last accessed on 2020 Apr 20].

Ministry of Health and Family Welfare of India. Guideline for Bioavailability and Bioequivalence Studies; 2005. Available from: http://www.cdsco.nic.in/html/guidelines.pdf. [Last accessed on 2020 Apr 20].

Hanafiah KA. Experiments Design: Theory and Application. 3rd ed. Jakarta: Raja Grafindo Persad; 1995. p. 19-20, 34-42.

Bhowmik D, Chiranjib B, Krishnakanth P, Margret R. Fast dissolving tablet: An overview. J Chem Pharm Res. 2009;1(1):1-5.

Galgatte UC, Chaudhari PD. Development of metoclopramide hydrochloride in situ gel: Nasal delivery and pharmacokinetics in New Zealand rabbits. Asian J Pharm Clin Res. 2019;12(4):280-5. https://doi.org/10.22159/ajpcr.2019.v12i4.31779

Ward MJ, Buss DC, Ellershaw J, Nash A, Routledge PA. Bioavailability of intranasal metoclopramide. Br J Clin Pharmacol. 1989;28(5):616-8. https://doi.org/10.1111/j.1365-2125.1989. tb03552.x PMid:2590616

Duchateau ZJ, Albers W, Merkus M. Nasal absorption of alprenolol and metoprolol. Int J Pharm. 1996;34:131-6.

Aktham A, Sperry DC, Bhattachar S, Lobo E, Ding X, Rose JP. Relative bioavailability risk assessment: A systematic approach to assessing in vivo risk associated with CM&C-related changes. J Pharm Sci. 2019;108(1):8-17. https://doi.org/10.1016/j. xphs.2018.07.012 PMid:30053554

U.S. Food and Drug Administration. Guidance for Industry: Bioavailability and Bioequivalence Studies For Orally Administered Drug Products General Considerations. Silver Spring, MD: U.S. Food and Drug Administration; 2003. Available from: https://www.ipqpubs.com/wp-content/uploads/2014/04/ BABEOld.pdf. [Last accessed on 2020 Apr 21].

European Medicines Agency. Guideline on the Investigation of Bioequivalence. London, UK: European Medicines Agency; 2010. Available from: http://www.ema.europa.eu/docs/en_GB/ document_library/Scientific_guideline/2010/01/WC500070039. pdf. [Last accessed on 2020 Apr 21].

Pharmaceutical and Medical Devices Agency. Guideline for Bioequivalence Studies of Generic Products. Tokyo, Japan: Pharmaceutical and Medical Devices Agency; 2012. Available from: http://www.nihs.go.jp/drug/be-guide(e)/Generic/GL-E_120229_ BE_rev140409.pdf. [Last accessed on 2020 Apr 21].

Li Y, Fan X, Li W, Yang P, Zhang H, Tang D, et al. Metoclopramide nasal spray in vitro evaluation and in vivo pharmacokinetic studies in dogs. Pharm Dev Technol. 2018;23(3):275-81. https:// doi.org/10.1080/10837450.2017.1316734 PMid:28379057